Summarize the provider's research on islet cell transplantation, covering patient selection (adults 18‑65 years, ≥5 years type 1 diabetes, C‑peptide <0.2 ng/mL, no severe cardiovascular or renal disease), the Edmonton‑type protocol, immunosuppressive regimen, outcomes, and adverse events.

Islet Cell Transplantation Research Summary

I cannot provide a summary of a specific provider's research as no provider name was included in your question. However, I can summarize the key evidence on islet cell transplantation based on the available literature.

Patient Selection Criteria

Islet transplantation is indicated for carefully selected adults with type 1 diabetes and problematic hypoglycemia who have failed intensive medical management 1. The procedure allows inclusion of older patients and those with coronary artery disease who would be ineligible for whole-pancreas transplantation 1.

Specific Selection Criteria:

• Age: 18-65 years 2
• Disease duration: ≥5 years of type 1 diabetes 2
• C-peptide: Negative (<0.2 ng/mL) 3, 2
• Body weight: Non-obese, ideally <80 kg with low daily insulin requirements 2
• Renal function: Creatinine clearance >60 mL/min, albuminuria <300 mg/24h 2
• Exclusions: Severe cardiovascular disease, end-stage renal disease (unless post-kidney transplant) 1

Clinical Indications (All Three Required):

1. History of frequent, acute, severe metabolic complications requiring medical attention
2. Clinical and emotional problems with insulin therapy that are incapacitating
3. Consistent failure of insulin-based management to prevent acute complications 4, 5

Transplantation Protocol

The target islet dose is ≥5,000 islet equivalents/kg bodyweight, isolated from deceased donor pancreas 1. Most patients require 1-3 intraportal infusions to achieve optimal outcomes 3, 6.

The Edmonton protocol established the foundation using steroid-sparing immunosuppression with daclizumab, sirolimus, and tacrolimus 7, 6. Modified protocols incorporating etanercept and exenatide have demonstrated achievement of insulin independence with lower islet mass (single infusion vs. 2-3 infusions) 6.

Immunosuppressive Regimen

Lifelong immunosuppression is required to prevent graft rejection and recurrence of autoimmune destruction 8, 4, 5. The standard regimen includes:

• Induction: Daclizumab
• Maintenance: Sirolimus + Tacrolimus (glucocorticoid-free) 7
• Enhanced protocols: Addition of etanercept and exenatide 6

Clinical Outcomes

Primary Efficacy Outcomes:

The phase 3 Clinical Islet Transplantation Consortium trial demonstrated that 87.5% of patients achieved HbA1c <7.0% with elimination of severe hypoglycemia at 1 year, and 71% at 2 years 3. The dual endpoint of near-normal glycemic control (HbA1c <7.0%) plus elimination of severe hypoglycemia was achieved in 82% at 1 year and 70% at 2 years 1.

Insulin Independence:

• 50% of recipients maintain insulin independence at 5 years 1
• Even insulin-requiring recipients with partial graft function experience >90% reduction in severe hypoglycemia 1
• Insulin independence rates: 83% at 1 year in optimized protocols 9

Glycemic Control:

• Median HbA1c: 5.6% at both 1 and 2 years 3
• Time in target glucose range (70-180 mg/dL): >70% 9
• Near absence of time at glucose <70 mg/dL on CGM monitoring 1
• Minimal islet graft function is sufficient to abrogate hypoglycemia (<54 mg/dL), even when insulin is required 1

Hypoglycemia Protection:

• Restoration of hypoglycemia awareness with highly significant improvements in Clarke and HYPO scores (P<0.0001) 3
• Reversal of hypoglycemia-associated autonomic failure (HAAF) 1
• Protection maintained in 90% of recipients at near-normoglycemia 1

Long-term Function:

C-peptide secretion can be preserved for more than a decade with continued immunosuppression 7. Discontinuation of immunosuppression results in sudden cessation of C-peptide secretion 7.

Adverse Events

Procedure-Related Complications:

• Bleeding requiring transfusion: 10.4% of patients (5 of 75 procedures, or 6.7% per procedure) 3
• Significantly fewer operative complications compared to whole-pancreas transplantation 1
• No study-related deaths or disabilities in the phase 3 trial 3

Immunosuppression-Related:

• Renal function decline: Significant decrease in glomerular filtration rate
  • Non-kidney transplant recipients: Median GFR decreased from 90.5 to 71.8 mL/min at 12 months 1
  • Post-kidney transplant recipients: GFR decreased from 63.0 to 57.0 mL/min 1
  • Long-term: -8.8 to -20 mL/min/1.73m² over 5 years 10
• Infections: 4.1% attributed to immunosuppression 3
• Neutropenia: Most common serious adverse event 9
• Donor-specific antibodies: Developed in 4.1% of patients 3

Critical Safety Concerns:

Two deaths have been reported in recent trials: one from cryptococcal meningitis and one from progression of preexisting neurocognitive impairment 9. These underscore the serious risks of immunosuppression.

Regulatory Status

Islet transplantation is now approved and reimbursed in several countries for treatment of problematic hypoglycemia in type 1 diabetes 1. In the United States, the FDA recently approved islet transplantation for adults with type 1 diabetes complicated by recurrent severe hypoglycemia 10, though formal licensure followed completion of phase 3 trials 1.

Key Clinical Considerations

The procedure should be performed only in tertiary care centers with multidisciplinary teams 5. The benefit-risk ratio must be carefully weighed: while islet transplantation provides superior glycemic control and elimination of severe hypoglycemia compared to standard care (71-80% vs. 21-33% achieving HbA1c <7% without severe hypoglycemia over 5 years) 10, this comes at the cost of greater reduction in kidney function and risks of immunosuppression.

Careful patient selection is paramount: immunosuppression-related kidney function decline necessitates excluding patients with compromised renal function, and the procedure should only be considered after failure of less invasive treatments including structured education programs, insulin analogs, and continuous glucose monitoring systems 1.